Maintaining Investments in New Innovation Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Maintaining Investments in New Innovation Act
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 5547: Maintaining Investments in New Innovation Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-5547/
"H.R. 5547: Maintaining Investments in New Innovation Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-5547/.
H.R. 5547, 118th Cong. (2026), https://openamerica.io/bill/118-HR-5547/.
[H.R. 5547: Maintaining Investments in New Innovation Act](https://openamerica.io/bill/118-HR-5547/)